Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Irinotecan oral - Hanmi Pharmaceutical

Drug Profile

Irinotecan oral - Hanmi Pharmaceutical

Alternative Names: Irinotecan + HM 30181A; Irinotecan + HM30181AK; Irinotecan + HM30181AK-US; Oral irinotecan - Hanmi Pharmaceutical; Oratecan

Latest Information Update: 04 Jun 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hanmi Pharmaceutical
  • Developer Athenex; Hanmi Pharmaceutical
  • Class Alkaloids; Antineoplastics; Camptothecins; Small molecules; Vinca alkaloids
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Colorectal cancer; Solid tumours

Most Recent Events

  • 31 May 2019 Efficacy and adverse events data from a phase I trial in Solid tumours presented at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO-2019)
  • 14 Nov 2018 Athenex plans a phase II trial for Solid tumors in in the first half of 2019
  • 12 Sep 2018 Athenex and Hanmi Pharmaceutical revise the collaboration agreement to grant Athenex the rights to develop and commercialise Orascovery™-based products in the Middle East, North Africa and South Africa
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top